Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers (APPROCHE ORL)

This study is currently recruiting participants.
Verified March 2014 by Centre Hospitalier Universitaire de Nīmes
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nīmes Identifier:
First received: April 14, 2010
Last updated: March 4, 2014
Last verified: March 2014

The purpose of this study is to determine if there is a correlation between tumor response after 3 doses of chemotherapy by induction using Docetaxel, Cisplatine and 5-Fluorouracile for advanced stage epidermoid carcinomas of the upper aero digestive tract and the presence of one or a combination of 3 genetic polymorphisms and/or 5 intra-tumoral transcriptional modifications.

Carcinoma, Squamous Cell
Mouth Neoplasms
Oropharyngeal Neoplasms
Laryngeal Neoplasms
Hypopharyngeal Neoplasms

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pharmacogenetic and Pharmacokinetic Aspects of the Response to Chemotherapy Induction Using Docetaxel, Cisplatin and 5-Fluorouracile (TPF)in ORL Cancers

Resource links provided by NLM:

Further study details as provided by Centre Hospitalier Universitaire de Nīmes:

Primary Outcome Measures:
  • %change in tumor volume before and after chemotherapy (baseline versus 62 days) [ Time Frame: 62 days ] [ Designated as safety issue: No ]
    Tumor volume is calculated according to Labadie et al 2000

Biospecimen Retention:   Samples With DNA

Surplus blood, tumor tissue from biopsies, and DNA will be stocked in the Biothèque of the Nîmes University Hospital

Estimated Enrollment: 100
Study Start Date: April 2010
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
All patients
As the trial progresses, patients will be classified as either chemotherapy responders or non-responders.


Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The patients included in this study have been diagnosed with an advanced stage squamous cell carcinoma in the buccal, oropharyngeal, laryngeal or hypopharyngeal areas.


Inclusion Criteria:

  • Squamous cell carcinoma originating in the mouth, oropharynx, larynx or hypopharynx has been histologically documented.
  • The disease is at one of the following UICC 2002 stages, regardless of ganglion status: T3 MO or T4 MO
  • Treatment via chemotherapy, radiotherapy or surgery (except for the diagnostic biopsy) has not started
  • The pluridisciplinary committee as ruled out surgical options for technical or functional reasons
  • Absence of distant metastases
  • OMS general health status between 0 and 2
  • Patient has given informed consent
  • Patient is affiliated with a social security system

Exclusion Criteria:

  • Undifferentiated squamous cell carcinomas in the nasopharynx (UCNT)
  • Another cancer priorly treated with one of the following chemotherapies: Docetaxel, Cisplatin, 5-Fluorouracile
  • Creatininemia > 2 mg/dl and/or creatinine clearance < 60ml/min
  • Patient under guardianship
  • Presence of another severe pathology including:

    • severe or chronic cardiac, renal and/or hepatic insufficiencies
    • severe medullary hypoplasia
    • severe autoimmune disease
    • psychosis or senility
  Contacts and Locations
Please refer to this study by its identifier: NCT01104714

Contact: Benjamin Lallemant, MD

CH d'Alès Recruiting
Alès, France, 30103
Principal Investigator: Didier Cupissol, MD         
Sub-Investigator: Caroline Alovisetti, MD         
CHU de Bordeaux - Groupe Hospitalier Saint-André Recruiting
Bordeaux, France, 33075
Sub-Investigator: Laurence Digue, MD         
CHU de Bordeaux - Groupe Hospitalier Pellegrin Recruiting
Bordeaux, France, 33076
Principal Investigator: Erwan De Mones, MD         
Sub-Investigator: Sandrine Eimer, MD         
CHU de Grenoble Recruiting
Grenoble cedex 09, France, 38043
Principal Investigator: Emile Reyt, MD         
Sub-Investigator: Christian Righini, MD         
Sub-Investigator: Claire Faure, MD         
Centre de Lutte Contre le Cancer - Centre Oscar Lambret Recruiting
Lille Cedex, France, 59020
Principal Investigator: Marian Degardin, MD         
CHU de Montpellier - Hôpital Gui de Chauliac Recruiting
Montpellier cedex 5, France, 34295
Principal Investigator: Renaud Garrel, MD         
Sub-Investigator: Valérie Costes, MD         
Centre Regional de Lutte Contre le Cancer - Val d'Aurelle - Paul Lamarque Recruiting
Montpellier cedex 5, France, 34298
Principal Investigator: Didier Cupissol, MD         
Centre Antoine Lacassagne Recruiting
Nice cedex 2, France, 06189
Principal Investigator: Frédéric Peyrade, MD         
CHU de Nîmes - Hôpital Universitaire Carémeau Recruiting
Nîmes, France, 30029
Principal Investigator: Benjamin Lallemant, MD         
Sub-Investigator: Pascal Roger, MD         
Sub-Investigator: Sophie Kacha, MD         
Sub-Investigator: Guillaume Chambon, MD         
Sub-Investigator: Charles Debrigode, MD         
Sub-Investigator: Mounira El Demery, MD         
Sub-Investigator: Nicolas Molinari, PhD         
Sub-Investigator: Jean-Pierre Daurès, MD, PhD         
Sub-Investigator: Jean-Paul Brouillet, MD         
Sub-Investigator: Alexandre Evrard, MD         
CHRU de Toulouse - Hôpital Larrey Recruiting
Toulouse, France, 31059
Principal Investigator: Sebastien Vergez, MD         
Sub-Investigator: Josiane Percodani, MD         
Sub-Investigator: Stéphanie Lozano, MD         
Pharmacologie Clinique, expérim. des anticancéreux, CLCC Claudius Regaud Recruiting
Toulouse, France, 31052
Principal Investigator: Etienne Chatelut, MD         
CHRU de Toulouse - Hôpital de Rangueil Recruiting
Toulouse, France, 31059
Sub-Investigator: Emmanuelle Uro-Coste, MD         
Centre de Lutte Contre le Cancer - Institut Claudius Regaud Recruiting
Toulouse Cedex, France, 31052
Principal Investigator: Jean Pierre Delord, MD         
Sub-Investigator: Michel Rives, MD         
Sub-Investigator: Adil Benlyazid, MD         
Sub-Investigator: Jérome Sarini, MD         
CHRU de Toulouse - Hôpital Purpan Recruiting
Toulouse Cedex 9, France, 31059
Sub-Investigator: Séverine Valmary, MD         
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nīmes
Principal Investigator: Benjamin Lallemant, MD Centre Hospitalier Universitaire de Nîmes
  More Information

Responsible Party: Centre Hospitalier Universitaire de Nīmes Identifier: NCT01104714     History of Changes
Other Study ID Numbers: LOCAL/2008/BL-01, 2008-006874-14
Study First Received: April 14, 2010
Last Updated: March 4, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
France: Committee for the Protection of Personnes

Additional relevant MeSH terms:
Mouth Neoplasms
Carcinoma, Squamous Cell
Hypopharyngeal Neoplasms
Laryngeal Neoplasms
Oropharyngeal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Laryngeal Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Mouth Diseases processed this record on April 23, 2014